OQS
CHRS icon

Occudo Quantitative Strategies’s Coherus Oncology CHRS Stock Holding History

Occudo Quantitative Strategies’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-70,529
Closed -$235K – 774
2023
Q4 		$235K Buy
+70,529
New +$189K 0.03% 610
2022
Q4 		– Sell
-26,754
Closed -$257K – 1018
2022
Q3 		$257K Sell
26,754
-11,359
-30% -$115K 0.02% 897
2022
Q2 		$276K Buy
+38,113
New +$331K 0.02% 816

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Occudo Quantitative Strategies's CHRS Position: Q1 2024 in Review

Occudo Quantitative Strategies sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 70,529 shares — an estimated $235K sold.

Occudo Quantitative Strategies first reported a position in CHRS in Q2 2022 and held it in 3 quarters. The position peaked at $276K in Q2 2022. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Occudo Quantitative Strategies reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 70,529 Coherus Oncology shares in Q1 2024, an estimated $235K.
  • Occudo Quantitative Strategies first reported a position in Coherus Oncology in Q2 2022 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Coherus Oncology position peaked at $276K in Q2 2022.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2024, filed 15 May 2024.